Polycystic Kidney Disease - Pipeline Review, H2 2016

Date: October 29, 2016
Pages: 87
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P26E4257DB1EN
Leaflet:

Download PDF Leaflet

Polycystic Kidney Disease - Pipeline Review, H2 2016
Polycystic Kidney Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2016, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 1, 11 and 2 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively for Polycystic Kidney Disease.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Polycystic Kidney Disease Overview
Therapeutics Development
Pipeline Products for Polycystic Kidney Disease - Overview
Pipeline Products for Polycystic Kidney Disease - Comparative Analysis
Polycystic Kidney Disease - Therapeutics under Development by Companies
Polycystic Kidney Disease - Therapeutics under Investigation by Universities/Institutes
Polycystic Kidney Disease - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Polycystic Kidney Disease - Products under Development by Companies
Polycystic Kidney Disease - Products under Investigation by Universities/Institutes
Polycystic Kidney Disease - Companies Involved in Therapeutics Development
Angion Biomedica Corp.
Aptevo Therapeutics Inc
DiscoveryBiomed, Inc.
Endocyte, Inc.
IC-MedTech, Inc.
Ipsen S.A.
Kadmon Corporation, LLC
ManRos Therapeutics
Metabolic Solutions Development Company, LLC
NovaTarg Therapeutics, Inc
Otsuka Holdings Co., Ltd.
XORTX Pharma Corp.
Polycystic Kidney Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(ascorbic acid + menadione) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANG-3070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CIM-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBM-43H11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-0371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JP-153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
menadione sodium bisulfite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSDC-0160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSDC-0602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxypurinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrimethamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STA-2842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tesevatinib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNFR x TWEAKR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tolvaptan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycystic Kidney Disease - Dormant Projects
Polycystic Kidney Disease - Discontinued Products
Polycystic Kidney Disease - Product Development Milestones
Featured News & Press Releases
Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease
Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015
May 28, 2015: Otsuka’s JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented “dual action” small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases
Mar 18, 2015: Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease
Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease
Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease
Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide
Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease
Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease
May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease
Mar 24, 2014: Otsuka Pharmaceutical's Samsca Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease
Dec 27, 2013: European Medicines Agency Accepts Otsuka's Marketing Authorisation Application for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease
Aug 29, 2013: Otsuka Receives Complete Response Letter from U.S. Food and Drug Administration for Tolvaptan for Use in Patients with Autosomal Dominant Polycystic Kidney Disease
Aug 05, 2013: U.S. Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee Recommends Not to Approve Otsuka Pharmaceutical’s Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 87

LIST OF TABLES

Number of Products under Development for Polycystic Kidney Disease, H2 2016
Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp., H2 2016
Polycystic Kidney Disease - Pipeline by Aptevo Therapeutics Inc, H2 2016
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed, Inc., H2 2016
Polycystic Kidney Disease - Pipeline by Endocyte, Inc., H2 2016
Polycystic Kidney Disease - Pipeline by IC-MedTech, Inc., H2 2016
Polycystic Kidney Disease - Pipeline by Ipsen S.A., H2 2016
Polycystic Kidney Disease - Pipeline by Kadmon Corporation, LLC, H2 2016
Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H2 2016
Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company, LLC, H2 2016
Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics, Inc, H2 2016
Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Polycystic Kidney Disease - Pipeline by XORTX Pharma Corp., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Polycystic Kidney Disease - Dormant Projects, H2 2016
Polycystic Kidney Disease - Discontinued Products, H2 2016 74

LIST OF FIGURES

Number of Products under Development for Polycystic Kidney Disease, H2 2016
Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Kidney Cancer - Pipeline Review, H1 2015 US$ 1,600.00 Jun, 2015 · 847 pages

Ask Your Question

Polycystic Kidney Disease - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: